- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers | 36 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif. and MIAMI, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| 29.03. | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 13.02. | Pasithea Therapeutics begins U.S. trial for cancer treatment | 2 | Investing.com | ||
| 18.01. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.01. | Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position | 129 | GlobeNewswire (Europe) | -- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO, Calif.... ► Artikel lesen | |
| 02.01. | Pasithea Jumps as FDA Grants IND Status to Cancer Treatment | 3 | Baystreet.ca | ||
| 02.01. | Pasithea Therapeutics' IND Application For PAS-004 Gets FDA Acceptance | 3 | RTTNews | ||
| 02.01. | Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study | 5 | Seeking Alpha | ||
| 02.01. | Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients | 236 | GlobeNewswire (Europe) | -- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024... ► Artikel lesen | |
| 28.12.23 | Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 | 3 | GlobeNewswire (USA) | ||
| 28.12.23 | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.12.23 | Pasithea Therapeutics Announces Results from 2023 Annual Meeting | 180 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ: KTTA), today announced that it held its annual meeting of... ► Artikel lesen | |
| 19.12.23 | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.12.23 | Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today? | 1 | InvestorPlace | ||
| 11.12.23 | Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today? | 2 | InvestorPlace | ||
| 11.12.23 | Pasithea stock soars as high as 190% on preclinical data | 2 | Seeking Alpha | ||
| 11.12.23 | Pasithea Announces Positive In Vivo Preclinical Data For PAS-004 | 1 | RTTNews | ||
| 11.12.23 | Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why | 1 | Benzinga.com | ||
| 11.12.23 | Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models | 208 | GlobeNewswire (Europe) | -- Preclinical data continues to demonstrate PAS-004's potentially superior properties as compared to FDA approved MEK inhibitors -- -- Once daily dose of PAS-004 delivers anti-tumor efficacy in... ► Artikel lesen | |
| 29.11.23 | Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders | 2 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,535 | -5,25 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| OCUGEN | 1,312 | +1,55 % | Ocugen Announces OCU400-Modifier Gene Therapy-Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 | MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,824 | -4,19 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,990 | 0,00 % | Ginkgo Bioworks surges as much as 31%, though pares gains | ||
| BEAM THERAPEUTICS | 22,050 | +3,13 % | Expert Ratings For Beam Therapeutics | ||
| GENPREX | 1,962 | +4,03 % | Genprex, Inc.: Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting | Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments
REQORSA Has Anti-Tumor Mechanisms and Ability to Trigger Cancer... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,030 | +1,98 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,630 | +0,30 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,848 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,830 | +0,46 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,740 | +0,07 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,370 | +1,70 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,260 | +1,62 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,600 | +2,99 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen |
PASITHEA THERAPEUTICS CORP gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
